Osimertinib is a targeted anti-cancer drug, primarily used in the treatment of non-small cell lung cancer (NSCLC). It belongs to the class of medications known as tyrosine kinase inhibitors (TKIs) and works by inhibiting the activity of the epidermal growth factor receptor (EGFR) with certain mutations, helping to slow or stop the growth of cancer cells.